All In Biotech

NDA 208470 · Millicent

Intrarosa

Prasterone · Vaginal

Last checked: Nov 20, 2026Latest source record: Feb 13, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Nov 16, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

95

43 Phase 3, 5 recruiting

FAERS reports

2,752

892 serious, 47 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 17, 2026.

INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 2016 Original approval · Type 2 New Active Ingredient and Type 4 New Combination LabelLetterReview
1 products under this application
  • INTRAROSA · PRASTERONE 6.5MG · INSERT, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Prasterone" as an intervention, any sponsor and status, largest first.

All 95 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use803
  • fatigue171
  • headache171
  • drug ineffective168
  • nausea132
  • product dose omission issue130
  • application site discharge115
  • rash95
  • dizziness94
  • insomnia93
  • pain92
  • vaginal discharge85

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20054
20084
20092
201011
201135
201258
20133
20146
201510
201619
201724
2018312
2019441
2020301
2021209
2022258
2023300
2024228
2025291
2026228

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Intrarosa (Prasterone (Dhea))

2024 spending

$4.3M

Beneficiaries

3,611

11,112 claims

Per beneficiary

$1,193

$9.27 per unit

View as table
YearSpending
2020$3,707,916
2021$3,774,126
2022$3,802,825
2023$3,782,382
2024$4,306,828

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Millicent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.